



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Myogenic induction of adult and pluripotent stem cells using recombinant proteins



Ilaria Perini ^a, Ilaria Elia ^{a,b}, Antonio Lo Nigro ^{c,d}, Flavio Ronzoni ^e, Emanuele Berardi ^a, Hanne Grosemans ^a, So-ichiro Fukada ^f, Maurilio Sampaolesi ^{a,g,*}

^a Translational Cardiology Laboratory, Embryo and Stem Cell Biology Unit, Dept of Development and Regeneration, KU Leuven, Belgium

^b Vesalius Research Center, Belgium and Department of Oncology, VIB, KU Leuven, Belgium

^c Mediterranean Institute for Transplantation and Advanced Specialized Therapies (IRCCS-ISMETT), Regenerative Medicine and Biomedical Technologies Unit, Palermo, Italy

^d Embryo and Stem Cell Biology Unit, Dept of Development and Regeneration, KU Leuven, Belgium

^e Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Switzerland

^f Laboratory of Molecular and Cellular Physiology, Pharmaceutical Sciences, Osaka University, Japan

^g Division of Human Anatomy, Dept of Public Health, Experimental and Forensic Medicine, University of Pavia, Italy

ARTICLE INFO

Article history:

Received 27 June 2015

Accepted 3 July 2015

Available online 8 July 2015

Keywords:

Magic-F1

Recombinant protein

Mesoangioblast

Embryonic stem cells

Myogenic differentiation

ABSTRACT

Met Activating Genetically Improved Chimeric Factor 1 (Magic-F1) is a human recombinant protein, derived from dimerization of the receptor-binding domain of hepatocyte growth factor. Previous experiments demonstrate that in transgenic mice, the skeletal muscle specific expression of Magic-F1 can induce a constitutive muscular hypertrophy, improving running performance and accelerating muscle regeneration after injury.

In order to evaluate the therapeutic potential of Magic-F1, we tested its effect on multipotent and pluripotent stem cells. In murine mesoangioblasts (adult vessel-associated stem cells), the presence of Magic-F1 did not alter their osteogenic, adipogenic or smooth muscle differentiation ability. However, when analyzing their myogenic potential, mesoangioblasts expressing Magic-F1 differentiated spontaneously into myotubes. Finally, Magic-F1 inducible cassette was inserted into a murine embryonic stem cell line by homologous recombination. When embryonic stem cells were subjected to myogenic differentiation, the presence of Magic-F1 resulted in the upregulation of Pax3 and Pax7 that enhanced the myogenic commitment of transgenic pluripotent stem cells.

Taken together our results candidate Magic-F1 as a potent myogenic stimulator, able to enhance muscular differentiation from both adult and pluripotent stem cells.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Muscle diseases are a group of heterogeneous disorders, due to structural or functional abnormalities in the skeletal muscle, which then lead to muscular waste and force decrease. Although muscle diseases still lack an effective therapy, several novel strategies are entering into clinical trials, including gene replacement, exon skipping, stem cell therapies and treatments to induce muscle hypertrophy [1,2]. Previous studies have been shown that inducing

hypertrophy (through loss of myostatin or IGF upregulation) ameliorates the muscular regeneration and attenuates the severity of the disease in animal model of muscular dystrophy [3,4]. Therefore, the possibility to induce muscular hypertrophy has also a potential clinical implication for the treatment of both genetic and acquired muscle diseases [5]. We previously showed that Magic-F1 (Met-Activating Genetically-Improved Chimeric Factor 1) is a recombinant protein able to induce a beneficial effect in dystrophic mice, due to the constitutive hypertrophy, that partially rescues the muscle phenotype [6]. Magic-F1 is derived from a repetition of the high-affinity receptor-binding domain of human hepatocyte growth factor (HGF). Thanks to its peculiar structure, Magic-F1 binds Met, HGF receptor, and elicits a selective pattern of biological responses, enhancing the myogenic differentiation process,

* Corresponding author. Translational Cardiology Laboratory, Stem Cell Biology and Embryology Unit, Department of Development and Regeneration, KU Leuven, Herestraat 49 – O&N4 – Bus 814 3000 Leuven, Belgium.

E-mail address: maurilio.sampaolesi@med.kuleuven.be (M. Sampaolesi).

protecting the muscle precursors against apoptosis, without stimulating cell proliferation.

Mesoangioblasts (MABs), vessel-associated progenitors, have been described in murine, canine and human skeletal muscle [7–9]. When transplanted, they are able to cross the blood vessels and differentiate into skeletal muscle *in vivo* [7,8]. A phase I/II clinical trial is ongoing to test the safety of intra-arterial allogeneic transplantation of MABs in Duchenne muscular dystrophy patients. Moreover, the technology of reprogramming adult somatic cells into induced pluripotent stem cells (iPSC) [10,11] has opened a wide range of future possibilities in terms of personalized medicine. Patient-specific iPSC could be corrected and induced to differentiate into skeletal muscle progenitors, offering an autologous and expandable source for cell transplantation. To reach this aim, different protocols have been described for the differentiation of murine pluripotent stem cells towards myogenic progenitors, by overexpressing the paired-box transcription factors Pax3 and/or Pax7 or by particular culture conditions [12–16]. Pax3-induced cells, derived from embryonic stem cells (ESCs) and isolated as PDGFR α ⁺/Flk1[−] population, engrafted in skeletal muscles of dystrophic mice, improving contractility [12,13]. The same results were obtained from iPSC, by overexpressing Pax7 [14]. Furthermore, Pax7-positive satellite-like cells, derived from ESCs or iPSC differentiation, have been isolated by fluorescence-activated cell sorting (FACS), using a novel antibody (SM/C-2.6). These muscle progenitors were able to differentiate into skeletal muscle fibers both *in vitro* and *in vivo* [15,16].

We recently reported that Magic-F1 is expressed in developing tissues of mesenchymal origin in Magic-F1 transgenic mice, where also Pax3 is expressed [17]. The fact that Magic-F1 could be responsible of muscular hypertrophy, cooperating with Pax3 signal pathway, in skeletal muscle precursor cells encouraged us to explore the myogenic potential of Magic-F1 in adult and embryonic stem cells.

Therefore here we investigated novel strategies to improve myogenic differentiation in adult and pluripotent stem cells with recombinant proteins, which in principle can be used as adjuvant compounds for a plethora of skeletal muscle regenerative applications.

2. Materials and methods

2.1. Cell cultures

C2C12 cell line was maintained in Dulbecco's modified Eagle's medium (DMEM) high glucose supplemented with 2 mM glutamine, 100 μ g/ml streptomycin and 100 U/ml penicillin, 1 mM sodium pyruvate and 10% FBS (all from GBCO).

MABs have been isolated, established and expanded as previously described [18,19]. The growing medium contains 20% Fetal Bovine Serum (FBS), 2 mM glutamine, 100 μ g/ml streptomycin, 100 U/ml penicillin and 1 mM sodium pyruvate.

Mouse ESCs KH2 were grown on feeder layer of mitotically inactivated Mouse Embryonic Fibroblasts (MEF) or feeder free, on gelatin-coated dish. Cells were passaged every 2–3 days and grown in medium containing 20% FBS, recombinant mouse leukemia inhibitory factor (1000 U/ml), MEK inhibitor (1 μ M, PD0325901 Axon Medchem) and GSK inhibitor (3 μ M, Chir99021 Axon Medchem).

2.2. Plasmids

Magic-F1 cDNA was cloned in pTRIPZ lentiviral vector (Thermo Scientific). Magic-F1 and GFP cDNA were cloned in pBS31 vector. The plasmids were sequenced using the Big Dye Terminator V3.1 kit

(ABI) and prepared by following standard procedures of PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen).

2.3. Viral production and infection

293 cells were transfected with 6 μ g of packaging plasmid (psPAX2, #12260 Addgene), 2 μ g of envelope plasmid (pMD2G, #12259 Addgene) and 4 μ g of transfer vector (pTRIPZ-Magic-F1 or pWPT-nlsLacZ, #12261 Addgene), using Lipofectamine 2000 (Invitrogen), following manufacturer's protocol. Virus containing supernatants were harvested 36–48 h post-transfection, filtered to remove cell debris and added into the well, where the day before C2C12 cells or MABs were plated. Medium was replaced 24 h after infection and after 48 h the antibiotic was added to select the infected cells.

2.4. ESCs inducible cell lines

KH2 transgenic lines have been generated following manufacturer's instruction (Gene targeting kit, Thermo Scientific). Briefly, KH2 cells, which contain two FRT-sites and an ATG-less, promoter-less hygromycin cassette, were nucleofected with 15 μ g of pBS31-GFP or -Magic-F1 (carrying the cDNAs, the PGK promoter and the ATG start codon) and 7.5 μ g of pCAGG-Flp plasmid (for the flippase enzyme expression), in a Nucleofector™ 2b Device (Lonza), following the instructions of Mouse ES cell Nucleofector® Kit (Lonza). Homologous recombination allowed the cDNA insertion, conferring hygromycin resistance. After 24 h, ESCs were re-plated on hygromycin-resistant MEF, with 150 μ g/ml of hygromycin. Expression of the transgenes was induced adding doxycycline (1 μ g/ml) to the medium.

2.5. Mesodermal differentiation assays

Myogenic differentiation of C2C12 cells was obtained by serum starvation in differentiation medium (DMEM with 2% heat-inactivated horse serum (HS), 2 mM glutamine, 1 mM sodium pyruvate), in presence of doxycycline (1 μ g/ml) when indicated. Myotube formation was evaluated by immunofluorescence analysis for sarcomeric myosin heavy chain (MyHC). Fusion index was calculated counting the nuclei inside the myotube, divided by the total number of nuclei. At least 4 different pictures for each condition and each time point were counted, using Image J software (<http://rsbweb.nih.gov/ij/>).

The MABs obtained were differentiated into adipocytes, osteocytes, smooth muscle, and skeletal muscle following protocols already present in the lab [18,19]. To test their myogenic potential, MABs were differentiated alone or in co-culture with nLacZ-C2C12 cell in DMEM containing 2% HS. After one week, immunofluorescence analysis for MyHC and X-gal staining were performed to check myotubes formation and label the C2C12 nuclei. The fusion index has been calculated comparing the immunofluorescence and the bright field images, counting the MABs nuclei (negative for X-gal staining) inside the myotubes, divided by the total number of MABs nuclei.

KH2 cells were detached with trypsin, counted and diluted at 10000 cells/ml in differentiation medium (DMEM high glucose with 0.1 mM nonessential amino acids, 100 μ g/ml streptomycin and 100 U/ml penicillin, 0.1 mM 2-mercaptoethanol, 5% HS and 10% FBS). 1000 cells were plated into each well of an ultralow attachment 96-wells plate (Corning). Forced aggregation was induced by centrifugation at 1600 rpm for 6 min. After 48 h the medium was changed, adding doxycycline (1 μ g/ml). EBs were collected at day 0, 3, 5 and 7 for RNA analysis. At day 7, EBs were collected and analyzed by FACS Canto or plated in fibronectin-coated 48 well

plate, to induce the myogenic differentiation in DMEM containing 5% HS. Myogenic differentiation was evaluated as number of myotubes per well.

2.6. LacZ staining

Cells were washed in PBS and with a fixing solution, containing glutaraldehyde, EDTA and $MgCl_2$. Wells were washed with washing buffer (with NP40 and deoxycholate). The LacZ staining was performed at 37 °C overnight, adding a solution with X-gal, potassium ferrocyanide and potassium ferricyanide.

2.7. Immunofluorescence analysis

Immunofluorescence analysis was performed as previously described [6]. Cells were incubated with primary antibodies against MyHC (MF20, hybridoma bank, University of Iowa), Nanog (14-5761-80, eBioscience), Oct4 (sc-8628, Santa Cruz) and Sox2 (ab 5603, Millipore) or isotype control and then with the appropriate FITC- or TRITC-conjugated secondary donkey antibodies (1:500, Invitrogen). Images were taken by Eclipse Ti microscope (Nikon) and merged by Image-Pro Plus 6.0 software.

2.8. Western blot analysis

Western blot was performed as previously described [6]. Membranes were incubated with antibodies against: HGF (sc-1357, Santa Cruz), Beta-Tubulin (05-661, Millipore), GFP (ab-5450, Abcam) and later with donkey horseradish peroxidase-coupled secondary antibody (1:5000, Invitrogen). Specific bands were detected with Chemiluminescent Peroxidase Reagent and pictures were taken with Geldoc (Biorad).

2.9. RNA extraction and analysis

Total RNA was extracted using GeneElute Mammalian Total RNA Miniprep Kit (Sigma), following the manufacturer's protocol. After reverse transcription (SuperScript™ III First-Strand Synthesis SuperMix kit, Invitrogen), Real-Time qPCR was performed, following the Syber Green Mix (Invitrogen) protocol, on real time system Realplex2 Master Cycler (Eppendorf) or on ViiA 7 Real-Time PCR system (Invitrogen).

Oct4 Fw 5' – CCAGGCAGGAGCAGAGTGG – 3'
 Oct4 Rv 5' – CCACGTCGGCCTGGGTGTAC – 3'
 Eomes Fw 5' – AGAACCGTGCCACAGACCAA – 3'
 Eomes Rv 5' – TGGTCACAGGTGCTGGACA – 3'
 Mxl1 Fw 5' – ACCACAGCCCTGACAACT – 3'
 Mxl1 Rv 5' – TGGGTGCACACCATAACACA – 3'
 T-Bra Fw 5' – GTCAGACCAAGATCGTTCT – 3'
 T-Bra Rv 5' – GATCGTTCTGTCAGACCAA – 3'
 Pax3 Fw 5' – TCCATCCGACCTGGTGCCAT – 3'
 Pax3 Rv 5' – TTCTCCAGTCCAGGCGTTG – 3'
 Pax7 Fw 5' – GCCTTCAACCACTTCTGC – 3'
 Pax7 Rv 5' – ACTGTGCTGCTCCATCTTG – 3'
 Gapdh Fw 5' – CGAGACCCCACTAACATCAAA – 3'
 Gapdh Rv 5' – CATTGCTGACAATCTTGAGTGA – 3'

2.10. FACS analysis

EBs were dissociated using Cell dissociation buffer enzyme free Hank's based (Invitrogen) counted and incubated with biotinylated anti-SM/C-2.6 antibody (kindly provided by Dr. Fukada) or with biotinylated Rat IgG isotype. After two washes in PBS, cells were incubated with APC-conjugated streptavidin. Samples were analyzed on Canto Flow cytometer (BD bioscience) or sorted with

FACSaria Flow cytometer (BD bioscience). Sorted cells were plated on matrigel in growing medium and, once confluent, differentiate into myotube in DMEM 5% HS.

2.11. Statistical analysis

The results are expressed as average \pm standard deviation (SD). When data distribution approximated normality and two groups were compared, a Student's t-test was used. When three or more groups were compared a two-way ANOVA was used. All statistical tests were performed via Prism software (GraphPad). Significance was set at $p < 0.05$ or $p < 0.001$.

3. Results

3.1. Generation and validation of inducible lentiviral vector for Magic-F1 expression

C2C12 were transduced with lentiviral particles carrying Magic-F1 cDNA and were differentiated into myotubes, in presence or absence of doxycycline. Immunofluorescence analysis for MyHC was performed at day 3, 5 and 7 (Fig. 1A). The efficacy of the inducible system and the expression of transgenic protein were verified by Western-blot analysis (Fig. 1B). In presence of Magic-F1, the myogenic differentiation was accelerated and C2C12 cells formed larger myotubes, with more nuclei compared to the control, as showed by fusion index analysis (Fig. 1C).

3.2. Effect of Magic-F1 expression on adult mesoangioblasts

Next we tested the effect of Magic-F1 expression on MABs, which were infected with lentiviral particle, for an inducible expression of the transgenic protein. The presence or absence of Magic-F1 did not alter their ability to differentiate towards adipocytes, osteocytes or smooth muscle (Fig. 2A). However, Magic-F1 expression was able to induce the differentiation of MABs into myotubes (Fig. 2A), even without the presence of myoblast cell line, normally required to stimulate the myogenic differentiation. When MABs were co-cultured with C2C12, Magic-F1 expressing cells better contribute to myogenic differentiation, as shown by their increased fusion index (Fig. 2B).

3.3. Generation of an inducible Magic-F1 or GFP transgenic ESC line

KH2 cells were nucleofected with targeting vectors containing Magic-F1 or GFP cDNA and cells, in which recombination has occurred, were selected with hygromycin. Induction of the transgene was achieved adding doxycycline in the medium and checked by Western Blot analysis (Suppl. Fig. 1A). Gene expression analysis, for self-renewal-controlling genes (Oct4, Sox2, Nanog, Tbx3, Rex1 and Stella), confirmed that the targeting did not alter their pluripotency (Suppl. Fig. 1B). The presence of Oct4, Nanog and Sox2 at protein levels was checked by immunofluorescence analysis on GFP KH2 and Magic-F1 KH2 ESCs (Suppl. Fig. 1C).

3.4. Effect of Magic-F1 expression on ESCs myogenic differentiation

ESCs were grown in feeder free conditions on gelatin-coated dishes and plated in ultralow attachment plate to generate embryoid bodies (EBs), after forced aggregation by centrifugation. At day 2, doxycycline was added to the medium and EBs were cultured for 7 days (Suppl. Fig. 2A). The RNAs isolated from Magic-F1 and GFP EBs were analyzed at different time points (day 0, 3, 5 and 7) for the expression of markers of primitive streak and early




Fig. 1. Magic-F1 inducible lentiviral vector tested on C2C12. (A) Immunofluorescence analysis for MyHC expression on Magic-F1 C2C12 in absence (–Dox) or presence of doxycycline (+Dox) after 3, 5 and 7 days of culture in differentiation medium. Nuclei were stained with DAPI. Scale bar = 50 μm. (B) Western Blot analysis for Magic-F1, upon induction with doxycycline in Magic-F1 C2C12; β-tubulin was used as loading control. (C) Graph showing the fusion index of C2C12 cells differentiated in presence (+Dox) or in absence (–Dox) of Magic-F1 at day 3, 5 and 7; n = 5, *p < 0.05.

mesoderm differentiation (Eomes, Mixl1 and T-Bra), in order to confirm the transition from a pluripotent to a mesodermal state (Suppl. Fig. 2B). In presence of Magic-F1, the expression of these markers shows an up-regulation at day 3 of differentiation, if compared to the control. Moreover, when Pax3 and Pax7 expression was evaluated at day 5, 7 and 9 of differentiation, the Real Time PCR (qRT-PCR) analysis showed a higher expression of these paired-box transcription factors, when Magic-F1 was present, especially at day 7 (Fig. 3A). At day 7, EBs were plated onto fibronectin-coated plates. After EBs-adhesion, cells spread out and

grow as a monolayer. To induce terminal differentiation, medium containing 5% of serum was added to the cells, as soon as they reached confluence. In presence of Magic-F1, the myogenic commitment of ESCs was enhanced, as shown by spontaneous myotubes formation (Fig. 3B), suggesting that Magic-F1 could increase the amount of muscle progenitors in differentiating EBs. The analysis of the number of MyHC positive myotubes per well confirmed the myogenic differentiation potential of the recombinant protein (Fig. 3C). In order to quantify and purely isolate these myogenic precursors from Magic-F1 induced EBs, SM/C-2.6




Fig. 2. Effect of Magic-F1 expression on adult mesoangioblasts. (A) Alkaline phosphatase staining of Magic-F1 transduced MABs and analysis of their differentiation abilities towards adipocytes, osteocytes, smooth muscle and myotubes in absence (–Dox) or presence of doxycycline (+Dox). Scale bar = 50 μm. (B) Myogenic differentiation of Magic-F1 transduced MABs in co-culture with nLacZ C2C12 cells: immunofluorescence for MyHC and X-gal staining were compared to calculate the fusion index, as the ratio of the number of X-gal negative nuclei inside the myotubes, versus the total number of X-gal negative nuclei. Scale bar = 50 μm; n = 5, *p < 0.05.




Fig. 3. Enhanced myogenic potential of Magic-F1 expressing ESCs. (A) qRT-PCR results for the expression of Pax3 and Pax7 in Magic-F1 and GFP-derived EBs in presence of doxycycline at day 0, 5, 7 and 9. Shown are Mean \pm SD of absolute quantification for the indicated genes, normalized using Gapdh (logarithmic scale, $n = 3$, * $p < 0.05$, ** $p < 0.001$). (B) Immunofluorescence analysis for MyHC showing myotubes formation in Magic-F1 or GFP KH2-derived EBs. Nuclei were stained with DAPI. Scale bar = 100 μ m. (C) Quantification of MyHC positive myotubes per well in Magic-F1 or GFP KH2 derived-EBs, $n = 3$ * $p < 0.001$.

antibody was used to detect satellite-like cells. Differentiated EBs were collected from the 96 wells on day 7 and stained for SM/C-2.6 antibody. FACS analysis showed that in presence of Magic-F1, SM/C-2.6 positive cells were detected on an average of 14%,

differently from their control (~2%, Fig. 4A). Finally, SM/C-2.6 positive cells were also positive for myogenic markers, as Pax3, Pax7 and Myf5 (Fig. 4B) and able to fully differentiated in myotubes (Fig. 4C) as previously reported [15].




Fig. 4. Purification of SM/C-2.6 from ESCs subjected to myogenic differentiation. (A) Quantification of SM/C-2.6 positive cells by FACS on disaggregated EBs of Magic-F1 KH2 with or without doxycycline at day 7; $n = 5$, * $p < 0.05$. Representative scatter plots showing the distribution of SM/C-2.6 positive cells are also reported. (B) Immunofluorescence analysis for Pax3, Pax7 and Myf5 in sorted SM/C-2.6 positive cells. Nuclei were stained with DAPI; scale bar = 50 μ m. (C) Examples of immunofluorescence analysis for MyHC in SM/C-2.6 positive cells subjected to myogenic differentiation. Nuclei were stained with DAPI; scale bar = 100 μ m.

4. Discussion

HGF is a pleiotropic cytokine that plays a role in a variety of normal cellular processes. HGF activates a tyrosine kinase-dependent signaling cascade, after binding the proto-oncogenic Met receptor [20]. During embryogenesis, this cytokine is involved in the detachment of myogenic precursor cells from the lateral dermamyotome and their subsequent migration into the limb buds [21], while in the adult, the HGF-Met pathway is activated in muscle regeneration after injury, activating satellite cells proliferation [22]. However, HGF administration to muscle cells inhibits muscle differentiation both *in vitro* and *in vivo* [22,23]. To overcome this limitation we generated Magic-F1 as human HGF-derived protein and showed that differently from HGF, Magic-F1 activates AKT, but not ERK signaling pathway [6]; thus, the transgenic protein does not have any mitogenic activity. *In vivo* studies have demonstrated that, following cardiotoxin treatment, regenerating centrally nucleated fibers in Magic-F1 transgenic mice appear to have a greater cross-sectional area compared to wild-type animals. This can be explained by the enhanced differentiation potential of satellite cells, which indeed displayed an earlier differentiation program *in vitro* compared to cells isolated from wild-type mice [6].

In this work we looked into the effect of Magic-F1 during the differentiation of adult and pluripotent stem cells toward skeletal muscles. Lentiviral vectors were generated for an inducible expression of Magic-F1 and tested in C2C12 cells, a useful model for myogenic differentiation, where the expression of the transgenic protein accelerated the process of myotube formation.

We previously reported the presence of myogenic precursors, named mesoangioblasts, which differ from satellite cells and express pericyte markers [7–9]. We also speculated that MABs could be positively affected by Magic-F1 and actively participate to the muscle hypertrophy observed in transgenic mice [6]. Here we proved that indeed the recombinant protein was able to induce myogenic differentiation in MABs, in absence of C2C12 or satellite cells. These results in adult stem cells encourage us to study the effect of the transgenic protein in pluripotent stem cells. Several protocols have been proposed to generate skeletal muscle progenitors from ESCs. Unfortunately, the efficiency of these protocols is limited by the insufficient signals that induce patterning of the paraxial mesoderm. Due to this limitation, the majority of published protocols depend on forced Pax3 or Pax7 transgene expression [12–14] or on isolation of ES-derived satellite-like cells by SM/C-2.6 antibody [15]. We decided to generate transgenic ES cell line, where the expression of Magic-F1 or GFP could be induced by doxycycline. The new transgenic lines were differentiated towards skeletal muscle, adapting the protocol from Ref. [15]. In presence of Magic-F1, primitive streak markers (Mixl1, T and Eomes) showed an upregulation on day 3, while Pax3 and Pax7 on day 7, suggesting the ability of the transgenic protein to enhance the myogenic commitment of ESCs. This observation was confirmed by FACS analysis for SM/C-2.6, which showed a strong increase of positive cells in the Magic-F1 expressing EBs. Sorting for SM/C-2.6 allowed us to isolate myogenic progenitors, expressing satellite cells markers (Pax3, Pax7 and Myf5), and able to differentiate into myotube.

In conclusion, our results demonstrate that Magic-F1 is an engineered factor that provides pro-differentiative clues towards myogenic commitments in both adult and embryonic stem cells. This ability makes Magic-F1 a potential candidate for regenerative medicine and a valuable tool to counteract muscle wastage in muscular diseases, such as cachexia and muscular dystrophies.

Author contribution

IP designed, performed, analyzed experiments; IE, ALN, FR, EB, HG performed and analyzed experiments; MS analyzed experiments, drafted the manuscript and provided funding.

Conflict of interest

None.

Acknowledgments

This work was supported by the contributions of “Opening The Future” Campaign (EJJ-OPTFUT-02010), CARE-MI FP7 (#QPG-394601), AFM Telethon (#18073), Programmafiancierung KUL PF/10/00300, CARIPLO (2007.5639; 2008.2005), FWO (#G060612N, #GOA8813N, #G088715N), GOA/11/012, IUAP-VII/07 and OT#09-053 grants. IP is supported by IWT (PhD fellowship). EB is supported by FWO Postdoctoral Fellowship (12D2813N) and FWO grant (1525315N). We thank Christina Vochten and Vicky Raets for professional/administrative assistance. A particular thank to Ron-doufonds voor Duchenne Onderzoek for their kind donations.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.bbrc.2015.07.022>.

Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.bbrc.2015.07.022>.

References

- [1] E. Berardi, D. Annibali, M. Cassano, S. Crippa, M. Sampaulesi, Molecular and cell-based therapies for muscle degenerations: a road under construction, *Front. Physiol.* 5 (2014) 119.
- [2] R.C. Smith, B.K. Lin, Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders, *Curr. Opin. Support Palliat. Care* 7 (2013) 352–360.
- [3] K.R. Wagner, A.C. McPherron, N. Winik, S.J. Lee, Loss of myostatin attenuates severity of muscular dystrophy in mdx mice, *Ann. Neurol.* 52 (2002) 832–836.
- [4] E.R. Barton, L. Morris, A. Musaro, N. Rosenthal, H.L. Sweeney, Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice, *J. Cell Biol.* 157 (2002) 137–148.
- [5] M. Cassano, M. Quattrocchi, S. Crippa, I. Perini, F. Ronzoni, M. Sampaulesi, Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass, *J. Muscle Res. Cell Motil.* 30 (2009) 243–253.
- [6] M. Cassano, S. Birelli, A. Finan, L. Benedetti, C. Omes, R. Boratto, F. Martin, M. Allegretti, V. Broccoli, G. Cusella De Angelis, P.M. Comoglio, C. Basilico, Y. Torrente, P. Michieli, G. Cossu, M. Sampaulesi, Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis, *PLoS One* 3 (2008) e3223.
- [7] M. Sampaulesi, Y. Torrente, A. Innocenzi, R. Tonlorenzi, G. D'Antona, M.A. Pellegrino, R. Barresi, N. Bresolin, M.G. De Angelis, K.P. Campbell, R. Bottinelli, G. Cossu, Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts, *Science* 301 (2003) 487–492.
- [8] M. Sampaulesi, S. Blot, G. D'Antona, N. Granger, R. Tonlorenzi, A. Innocenzi, P. Mogno, J.L. Thibaud, B.G. Galvez, I. Barthelemy, L. Perani, S. Mantero, M. Guttinger, O. Pansarasa, C. Rinaldi, M.G. Cusella De Angelis, Y. Torrente, C. Bordignon, R. Bottinelli, G. Cossu, Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs, *Nature* 444 (2006) 574–579.
- [9] A. Dellavalle, M. Sampaulesi, R. Tonlorenzi, E. Tagliafico, B. Sacchetti, L. Perani, A. Innocenzi, B.G. Galvez, G. Messina, R. Morosetti, S. Li, M. Belicchi, G. Peretti, J.S. Chamberlain, W.E. Wright, Y. Torrente, S. Ferrari, P. Bianco, G. Cossu, Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells, *Nat. Cell Biol.* 9 (2007) 255–267.
- [10] K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, *Cell* 126 (2006) 663–676.
- [11] K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda, S. Yamanaka, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, *Cell* 131 (2007) 861–872.

- [12] R. Darabi, K. Gehlbach, R.M. Bachoo, S. Kamath, M. Osawa, K.E. Kamm, M. Kyba, R.C. Perlingeiro, Functional skeletal muscle regeneration from differentiating embryonic stem cells, *Nat. Med.* 14 (2008) 134–143.
- [13] R. Darabi, J. Baik, M. Clee, M. Kyba, R. Tupler, R.C. Perlingeiro, Engraftment of embryonic stem cell-derived myogenic progenitors in a dominant model of muscular dystrophy, *Exp. Neurol.* 220 (2009) 212–216.
- [14] R. Darabi, W. Pan, D. Bosnakovski, J. Baik, M. Kyba, R.C. Perlingeiro, Functional myogenic engraftment from mouse iPS cells, *Stem Cell Rev.* 7 (2011) 948–957.
- [15] H. Chang, M. Yoshimoto, K. Umeda, T. Iwasa, Y. Mizuno, S. Fukada, H. Yamamoto, N. Motohashi, Y. Miyagoe-Suzuki, S. Takeda, T. Heike, T. Nakahata, Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells, *FASEB J.* 23 (2009) 1907–1919.
- [16] Y. Mizuno, H. Chang, K. Umeda, A. Niwa, T. Iwasa, T. Awaya, S. Fukada, H. Yamamoto, S. Yamanaka, T. Nakahata, T. Heike, Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells, *FASEB J.* 24 (2010) 2245–2253.
- [17] F. Ronzoni, M. Bongio, S. Conte, L. Vercesi, M. Cassano, C. Tribioli, D. Galli, R. Bellazzi, G. Magenes, M.G. Cusella De Angelis, M. Sampaolesi, Localization of Magic-F1 transgene, involved in muscular hypertrophy, during early myogenesis, *J. Biomed. Biotechnol.* 2011 (2011) 492075.
- [18] R. Tonlorenzi, A. Dellavalle, E. Schnapp, G. Cossu, M. Sampaolesi, Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues, *Curr. Protoc. Stem Cell Biol.* Chapter 2 (2007). Unit 2B 1.
- [19] M. Quattrocchi, G. Palazzolo, I. Perini, S. Crippa, M. Cassano, M. Sampaolesi, Mouse and human mesoangioblasts: isolation and characterization from adult skeletal muscles, *Methods Mol. Biol.* 798 (2012) 65–76.
- [20] T. Nakamura, K. Sakai, T. Nakamura, K. Matsumoto, Hepatocyte growth factor twenty years on: much more than a growth factor, *J. Gastroenterol. Hepatol.* 26 (Suppl. 1) (2011) 188–202.
- [21] B. Christ, B. Brand-Saberi, Limb muscle development, *Int. J. Dev. Biol.* 46 (2002) 905–914.
- [22] R. Gal-Levi, Y. Leshem, S. Aoki, T. Nakamura, O. Halevy, Hepatocyte growth factor plays a dual role in regulating skeletal muscle satellite cell proliferation and differentiation, *Biochim. Biophys. Acta* 1402 (1998) 39–51.
- [23] Y. Leshem, D.B. Spicer, R. Gal-Levi, O. Halevy, Hepatocyte growth factor (HGF) inhibits skeletal muscle cell differentiation: a role for the bHLH protein twist and the cdK inhibitor p27, *J. Cell. Physiol.* 184 (2000) 101–109.